InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Bogle Grant C., Director. Director active across 2 companies, notably Epizyme, Inc.. Aggregated, 10 filings have been logged. Activity tracked since 11 June 2021. The latest transaction was disclosed on 15 July 2026 (U). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Bogle Grant C.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations10 total
3,714 shares@ US$124.000.0047% mcap100.0% of flowClass A Common StockSEC:0001193125-26-305051:0
5,577 sharesClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305051:1
3,444 sharesClass A Common StockSEC:0001646675-26-000002:0
2,647 shares0Class A Common StockSEC:0000950170-25-088545:0
3,200 shares0Class A Common StockSEC:0000950170-24-134328:0
84,170 sharesCommon Stock, par value $0.0001SEC:0000899243-22-028851:0
800,000 shares@ US$1.39100.0% of flowCommon Stock, par value $0.0001SEC:0000899243-22-028421:0
87,500 shares0Common Stock, par value $0.0001SEC:0000899243-22-004828:0
87,500 shares0Common Stock, par value $0.0001SEC:0000899243-21-033401:0
8,060 shares0Common Stock, par value $0.0001SEC:0000899243-21-023877:0
10 of 10 declarations
About Bogle Grant C.
Administrator of Nuvalent, Inc. and formerly President and CEO of Epizyme, Inc., Bogle Grant C. is a declarant with 10 filings in total. In the sampled recent filings, the buy and sell amounts are 0, the period runs from 2021-06-15 to 2026-07-15, and the most frequent transaction nature is Attribution.
